Navigation Links
BioMS Medical Announces Third Quarter 2008 Results
Date:11/6/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, Nov. 6 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the third quarter ended September 30, 2008. BioMS Medical, in partnership with Eli Lilly and Company (Lilly), is developing dirucotide (MBP8298), a drug for the treatment of MS undergoing pivotal trials in Canada, Europe and the U.S.

"The third quarter saw positive developments in the dirucotide development plan, with completion of the interim analysis resulting in a significant milestone payment from our partner Lilly," said Kevin Giese, President and CEO of BioMS Medical. "Dirucotide was also granted fast track designation by the U.S. FDA, another important achievement which could potentially accelerate the development and review process for this important MS drug."

Currently, BioMS is conducting three clinical trials and one open-label follow-on trial for dirucotide (MBP8298):

- MAESTRO-01: A randomized, double-blind pivotal phase II/III trial in

Canada and Europe evaluating dirucotide (MBP8298) for the treatment

of secondary progressive MS (SPMS). The study has completed full

recruitment of 611 patients at 47 trial sites in 9 countries. To

date, there have been nine positive safety reviews from the Data

Safety Monitoring Board (DSMB). Full analysis of this trial is

expected in the second half of 2009.

- MAESTRO-02: An open-label follow-on study to the MAESTRO-01 pivotal

trial. Eligible patients who have successfully completed the blinded,

placebo controlled MAESTRO-01 trial may choose to receive dirucotide

(MBP8298) on an un-blinded basis. To date, approximately 95% of

patients enrolled in MAESTRO-01 have proceeded to MAESTRO-02.

- MAESTRO-03: A U.S. pivotal phase III trial evaluatin
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... York, NY (PRWEB) September 18, 2014 ... completed negotiations with Salem Realty Group and has acquired ... development space within the Salem Executive Complex adjacent to ... ceremony was held on Friday September 5th. Whitehouse Labs ... refit the entire space specifically for package testing. The ...
(Date:9/17/2014)... SEATTLE, WA , Sept. 17, 2014 /PRNewswire/ - ... that it intends to offer and sell shares of ... in separate but concurrent underwritten public offerings.  The Series ... shares of Oncothyreon Common Stock, provided that conversion will ... its affiliates would beneficially own more than 4.99% of ...
(Date:9/17/2014)... -- MiMedx Group, Inc. (NASDAQ: MDXG ), ... protected regenerative biomaterials and bioimplants processed from human ... clinical study.    The study article, ... Trial Evaluating the Use of Dehydrated ... Therapy vs. Multi-layer Compression Therapy Alone in the ...
(Date:9/17/2014)... September 17, 2014 Immunomic Therapeutics, Inc. ... Research (SBIR) grant to support the continued preclinical development ... ITI with approximately $255,000 over one year to conduct ... of food allergy, affect over one million Americans and ... allergy. Tree nut exposure is also a risk for ...
Breaking Biology Technology:Whitehouse Labs Announces Package Testing Laboratory Expansion 2Whitehouse Labs Announces Package Testing Laboratory Expansion 3Whitehouse Labs Announces Package Testing Laboratory Expansion 4Oncothyreon Announces Proposed Public Offerings 2MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 2MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 3MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 4Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 3
... , Strategic Examination and Consolidation of Services Recommended ... 27 Little uniformity exists in the structure or functions of ... to Clinical Trials Offices: What,s New in Research Administration?, ... (AAHC). Emerging centralized clinical trial offices (CTOs) are among the ...
... , , ATLANTA, Aug. 27 ... million extension of its Series C financing which was originally completed in ... $5 million in Series C preferred stock received warrants for an additional ... have up to 30 days from the delivery of Phase III top-line ...
... , , , ... ATLANTA, Aug. 27 Airo, recognized maker of the ... Safe handset is available for delivery Q4 of 2009. Airo ... in potentially explosive environments like Petroleum, Chemicals, Fertilizer, Coal, Propane, ...
Cached Biology Technology:Clinical Trials Offices Changing Academic Health Center Research Infrastructure 2Alimera Sciences Closes $5 Million in Extended Series C Financing 2Airo Wireless Announces the Release of the Intrinsically Safe A25is Cell Phone/PDA 2
(Date:9/17/2014)... significantly faster since the 1960s. The typical development phases ... have accelerated -- by as much as 70 percent. ... by scientists from Technische Universitt Mnchen based on long-term ... observed since 1870. Their findings were published recently in ... dieback" was a hot topic, with the very survival ...
(Date:9/17/2014)... of bacterial infections, including MRSA and MSSA could ... bumps that mimic the scaly surface of shark ... access journal Antimicrobial Resistance and Infection Control ... materials prevented the spread of human disease bacteria ... Sharklet, is an arrangement of ridges formulated to ...
(Date:9/16/2014)... North American Menopause Society (NAMS) has published its ... midlife womenon everything from hot flashes to heart ... Society Recommendations for Clinical Care of Midlife Women," ... Menopause . This is the first, comprehensive ... midlife women freely available to all clinicians who ...
Breaking Biology News(10 mins):Global change: Trees continue to grow at a faster rate 2Global change: Trees continue to grow at a faster rate 3Sharks' skin has teeth in the fight against hospital superbugs 2
... July 20, 2011Researchers at the U.S. Department of Energy,s ... Center have found a potential key for unlocking the ... leaves and stalks, or switch grass. In a ... Chemical Society , Los Alamos researchers S. Gnanakaran, Giovanni ...
... sleuthing the 2010 Deepwater Horizon oil spill, a research team ... chemicals were contained in a deep, hydrocarbon-containing plume. The ... mapped and sampled it last summer in the Gulf of ... spill. The researchers took a major step in explaining ...
... Bureau of Reclamation and Fluid Imaging Technologies Inc. have ... the capacity and speed of Fluid Imaging Technologies, FlowCAM ... larvae in water samples. The spread of mussels ... impair or interrupt water delivery and hydropower generation functions ...
Cached Biology News:Researchers find potential key for unlocking biomass energy 2Chemical make-up of Gulf of Mexico plume determined 2Chemical make-up of Gulf of Mexico plume determined 3Chemical make-up of Gulf of Mexico plume determined 4Reclamation signs research agreement to improve quagga and zebra mussel larvae detection 2
The new Silencer siRNA Starter Kit is perfect for researchers new to RNAi. It provides all of the reagents, protocols, and instructions necessary to get underway with siRNA transfection and ensure su...
... working in a regulated environment, Pipette ... calibration software that automates gravimetric pipette ... framework that meets todays regulatory compliance ... secure solution that includes a full ...
... of the yolk protein Vtg in plasma from ... sensitive biomarker for endocrine disrupting chemicals (EDCs) with ... become an accepted screening test for the estrogenic ... trout) EIA kit is a double-antibody immunometric (sandwich) ...
... (RTL) can provide you with the ... method development and validation ,Performance of ... of your GMP manufacturing environment ,Assurance ... a full spectrum of microbiological services ...
Biology Products: